- Report
- September 2025
- 250 Pages
Global
From €4016EUR$4,490USD£3,533GBP
- Report
- September 2025
- 149 Pages
Global
From €2280EUR$2,549USD£2,006GBP
€2682EUR$2,999USD£2,360GBP
- Report
- February 2025
- 144 Pages
Global
From €2280EUR$2,549USD£2,006GBP
€2682EUR$2,999USD£2,360GBP
- Report
- April 2025
- 189 Pages
Global
From €4025EUR$4,500USD£3,541GBP
- Report
- February 2023
- 336 Pages
Global
From €4292EUR$4,799USD£3,776GBP
- Report
- April 2025
- 85 Pages
India
From €3131EUR$3,500USD£2,754GBP
- Report
- August 2023
- 145 Pages
Global
From €2818EUR$3,150USD£2,478GBP
- Report
- July 2021
- 120 Pages
Global
From €2236EUR$2,500USD£1,967GBP
- Report
- November 2022
- 220 Pages
Global
From €3086EUR$3,450USD£2,714GBP
- Report
- April 2024
- 90 Pages
Global
From €3500EUR$4,192USD£3,186GBP
- Report
- January 2025
- 132 Pages
Global
From €850EUR$950USD£747GBP
Biosimilar Monoclonal Antibodies (mAbs) are biotechnological products that are similar to existing monoclonal antibodies (mAbs) that are already approved for use in humans. Biosimilar mAbs are developed using recombinant DNA technology and are designed to have the same structure and function as the original mAbs. Biosimilar mAbs are used to treat a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. They are also used in research and development of new treatments.
The biosimilar mAbs market is growing rapidly due to the increasing demand for mAbs in the treatment of various diseases. The market is expected to continue to grow as more mAbs are developed and approved for use in humans. Additionally, the increasing demand for mAbs in research and development is expected to drive the growth of the market.
Some companies in the biosimilar mAbs market include Amgen, Biogen, Merck, Pfizer, and Novartis. Show Less Read more
